Brown Advisory Inc. Has $7.41 Million Position in Jounce Therapeutics Inc (JNCE)
Brown Advisory Inc. increased its position in shares of Jounce Therapeutics Inc (NASDAQ:JNCE) by 55.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 475,719 shares of the company’s stock after purchasing an additional 170,661 shares during the period. Brown Advisory Inc. owned 1.48% of Jounce Therapeutics worth $7,411,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Fosun International Ltd acquired a new position in shares of Jounce Therapeutics during the second quarter worth $1,456,000. Conning Inc. grew its stake in shares of Jounce Therapeutics by 36.0% during the third quarter. Conning Inc. now owns 125,960 shares of the company’s stock worth $1,962,000 after purchasing an additional 33,350 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Jounce Therapeutics by 465.7% during the second quarter. Goldman Sachs Group Inc. now owns 69,648 shares of the company’s stock worth $977,000 after purchasing an additional 57,336 shares in the last quarter. Geode Capital Management LLC acquired a new position in shares of Jounce Therapeutics during the first quarter worth $1,573,000. Finally, Wells Fargo & Company MN grew its stake in shares of Jounce Therapeutics by 476.1% during the second quarter. Wells Fargo & Company MN now owns 20,970 shares of the company’s stock worth $294,000 after purchasing an additional 17,330 shares in the last quarter. Hedge funds and other institutional investors own 47.55% of the company’s stock.
Jounce Therapeutics Inc (NASDAQ:JNCE) opened at $15.08 on Tuesday. Jounce Therapeutics Inc has a 12 month low of $11.05 and a 12 month high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.12. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The company had revenue of $18.10 million during the quarter, compared to the consensus estimate of $20.00 million. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. equities research analysts expect that Jounce Therapeutics Inc will post -0.77 earnings per share for the current fiscal year.
A number of equities analysts recently commented on JNCE shares. Zacks Investment Research downgraded shares of Jounce Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Robert W. Baird reiterated a “buy” rating and set a $30.00 target price on shares of Jounce Therapeutics in a research note on Tuesday, September 12th. Finally, J P Morgan Chase & Co set a $28.00 target price on shares of Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.
COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/05/brown-advisory-inc-has-7-41-million-position-in-jounce-therapeutics-inc-jnce.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.